Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Caribou Biosciences, Inc. presented at the Jefferies Global Healthcare Conference 2026. The company's CEO, Rachel Haurwitz, discussed their CRISPR genome editing platform and ongoing CAR-T cell therapy programs. They are currently advancing two programs targeting non-Hodgkin lymphoma and multiple myeloma.
- ▪Caribou Biosciences, Inc. is a CRISPR genome editing company.
- ▪They are developing off-the-shelf CAR-T cell therapies for hematologic malignancies.
- ▪The company is advancing two programs: vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4912499-caribou-biosciences-inc-crbu-presents-at-jefferies-global-healthcare-conference-2026"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
